Name | Burfiralimab |
---|
Description | Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1]. |
---|---|
Related Catalog | |
References |
No Any Chemical & Physical Properties |